July 12, 2025 06:00 AM EDT
Weekly

Bio­phar­ma’s high­est-paid CEOs; John Car­roll’s Q2 analy­sis; Mer­ck to buy Verona Phar­ma for $10B; and more

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

Wel­come back to End­points Week­ly! This week’s re­cap kicks off with the first in­stall­ment of an End­points News se­ries on pay in bio­phar­ma. Se­nior bio­phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­phar­ma's 20 high­est-paid CEOs of 2024 with $20M+ pay­days

Who pays the most in bio­phar­ma? We an­a­lyzed me­di­an pay at 177 com­pa­nies

Biotech’s Q2 num­bers paint a pic­ture of the good, the bad and the ug­ly

FDA's Makary calls for ty­ing fast-re­view vouch­ers to low­er US prices, with­out specifics

Up­dat­ed: Mer­ck drops $10B for res­pi­ra­to­ry drug­mak­er Verona Phar­ma in its first ac­qui­si­tion of 2025

sponsored

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

A service from the Financial Times